Richardus Vonk

1.0k total citations
26 papers, 819 citations indexed

About

Richardus Vonk is a scholar working on Cancer Research, Genetics and Statistics and Probability. According to data from OpenAlex, Richardus Vonk has authored 26 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 7 papers in Genetics and 7 papers in Statistics and Probability. Recurrent topics in Richardus Vonk's work include Cancer Genomics and Diagnostics (6 papers), Statistical Methods in Clinical Trials (6 papers) and Estrogen and related hormone effects (5 papers). Richardus Vonk is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Statistical Methods in Clinical Trials (6 papers) and Estrogen and related hormone effects (5 papers). Richardus Vonk collaborates with scholars based in Germany, United States and United Kingdom. Richardus Vonk's co-authors include Edmund Maser, Thomas Steger‐Hartmann, R. Länge, Stephan Goller, Iris Fuchs, Christiane Otto, Karl‐Heinrich Fritzemeier, Branko Zevnik, Gunther Kauselmann and Michael Schoor and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Richardus Vonk

25 papers receiving 801 citations

Peers

Countries citing papers authored by Richardus Vonk

Since Specialization

Citations

This map shows the geographic impact of Richardus Vonk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richardus Vonk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richardus Vonk more than expected).

Fields of papers citing papers by Richardus Vonk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richardus Vonk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richardus Vonk. The network helps show where Richardus Vonk may publish in the future.

Co-authorship network of co-authors of Richardus Vonk

This figure shows the co-authorship network connecting the top 25 collaborators of Richardus Vonk. A scholar is included among the top collaborators of Richardus Vonk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richardus Vonk. Richardus Vonk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Histology independent drug development – Is this the future for cancer drugs? 2023 ·Cancer Treatment Reviews ·Lucinda Billingham, (unknown), Theodor Framke, Alastair Greystoke, Eivind Hovig, (unknown), Philippe Page, (unknown), Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer	1
2	Assessing goodness‐of‐fit for evaluation of dose‐proportionality 2020 ·Pharmaceutical Statistics ·Martin J. Wolfsegger, (unknown), (unknown), Helmut Schütz, Richardus Vonk, Benjamin Lang, Stephan Lehr, Thomas Jaki, Werner Engl, Michael Hale	3
3	A proposal for a new PhD level curriculum on quantitative methods for drug development 2018 ·Pharmaceutical Statistics ·Thomas Jaki, A. Gordon, (unknown), Luc Bijnens, (unknown), Werner Brannath, Roberto Fontana, Mauro Gasparini, (unknown), Tom Jacobs, Byron Jones, Xavier Paolettí, Martin Posch, Andrew Titman, Richardus Vonk, Franz Koenig	4
4	The rat bone marrow micronucleus test: Statistical considerations on historical negative control data 2018 ·Regulatory Toxicology and Pharmacology ·(unknown), Annette Bitsch, Frank Bringezu, (unknown), Martina Dammann, Roland Frötschl, (unknown), Rupert Kellner, (unknown), (unknown), (unknown), Stefan Pfuhler, Nina Queisser, Markus Schulz, Andreas Sutter, Lea Vaas, Richardus Vonk, (unknown), Christina Ziemann	16
5	A statistical approach for analyzing data from the in vivo Pig-a gene mutation assay 2018 ·Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·(unknown), Stephen D. Dertinger, Vasily N. Dobrovolsky, Marian Raschke, Andreas Sutter, Richardus Vonk	0
6	Model selection based on combined penalties for biomarker identification 2017 ·Journal of Biopharmaceutical Statistics ·Eleni Vradi, Werner Brannath, Thomas Jaki, Richardus Vonk	2
7	Redefining the role of biomarkers in heart failure trials: expert consensus document 2017 ·Heart Failure Reviews ·Frank Kramer, Hani N. Sabbah, (unknown), Faı̈ez Zannad, J. Peter van Tintelen, Erik B. Schelbert, Raymond J. Kim, Hendrik Milting, Richardus Vonk, (unknown), Richard L. Clark, Klaus K. Witte, Wilfried Dinh, Burkert Pieske, Javed Butler, Mihai Gheorghiade	16
8	Increasing the efficiency of oncology basket trials using a Bayesian approach 2017 ·Contemporary Clinical Trials ·Rong Liu, Zheyu Liu, Mercedeh Ghadessi, Richardus Vonk	40
9	AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection 2016 ·BMC Cancer ·Marion Rudolph, Tobias Anzeneder, (unknown), Georg Beckmann, Annette T. Byrne, Michael Jeffers, Carol E. Peña, Oliver Politz, Karl Köchert, Richardus Vonk, Joachim Reischl	66
10	Abstract 5239: KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or metastatic pancreatic cancer (PC) treated with the MEK inhibitor refametin 2015 ·Cancer Research ·Michael Teufel, Jean‐Luc Van Laethem, Hanno Riess, Marius Giurescu, (unknown), (unknown), Richardus Vonk, Henrik Seidel, Joachim Reischl, Barrett H. Childs	2
11	A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice 2015 ·Endocrinology ·Christiane Otto, (unknown), Anne Ljungars, Siegmund S. Wolf, (unknown), Iris Fuchs, (unknown), (unknown), Richardus Vonk, Axel Harrenga, Christoph Freiberg	13
12	2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome 2015 ·European Journal of Cancer ·Michael Teufel, J. Kalmus, Mark Rutstein, Karl Köchert, Henrik Seidel, Joachim Reischl, (unknown), Richardus Vonk, (unknown), (unknown), Sida Qin, Rui‐Hua Xu, (unknown), (unknown)	4
13	Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial. 2015 ·Journal of Clinical Oncology ·Michael Teufel, Susanne Schwenke, Henrik Seidel, Georg Beckmann, Joachim Reischl, Richardus Vonk, Heinz‐Josef Lenz, Josep Tabernero, Salvatore Siena, Axel Grothey, Eric Van Cutsem, Michael Jeffers, Scott M. Wilhelm, Thierry André, Dirk Laurent, (unknown), Mark Rutstein, Pratyaksha Wirapati, Justin Guinney, Sabine Tejpar	20
14	A dynamic model of circadian rhythms in rodent tail skin temperature for comparison of drug effects 2012 ·SHILAP Revista de lepidopterología ·(unknown), Karsten Keller, Katja Prelle, Vladimir K. Patchev, Richardus Vonk, (unknown)	11
15	Willingness to Donate Human Samples for Establishing a Dermatology Research Biobank: Results of a Survey 2011 ·Biopreservation and Biobanking ·(unknown), Arndt A. Schmitz, Richardus Vonk, Frederik H. Igney, Wolf‐Dietrich Döcke, Stefanie Schoepe, Wolfram Sterry, Khusru Asadullah	2
16	Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate 2009 ·Maturitas ·Christiane Otto, Iris Fuchs, Richardus Vonk, Karl‐Heinrich Fritzemeier	4
17	In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro 2008 ·The Journal of Steroid Biochemistry and Molecular Biology ·Christiane Otto, Iris Fuchs, (unknown), (unknown), (unknown), Rolf Bohlmann, Duy Nguyen, (unknown), Richardus Vonk, Katja Prelle, T. Österman, (unknown), Karl‐Heinrich Fritzemeier	19
18	GPR30 Does Not Mediate Estrogenic Responses in Reproductive Organs in Mice 2008 ·Biology of Reproduction ·Christiane Otto, Iris Fuchs, Gunther Kauselmann, (unknown), Branko Zevnik, (unknown), (unknown), (unknown), (unknown), Michael Schoor, Richardus Vonk, Karl‐Heinrich Fritzemeier	230
19	Assessing non‐inferiority of a new treatment in a three‐arm trial in the presence of heteroscedasticity 2007 ·Statistics in Medicine ·Mario Hasler, Richardus Vonk, Ludwig A. Hothorn	36
20	Adverse Event Analysis and MedDRA: Business as Usual or Challenge? 2005 ·Drug Information Journal ·(unknown), Richardus Vonk, (unknown), (unknown), Martin Homering, (unknown), (unknown), (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact